Article Information
History
- February 20, 2020.
Article Versions
- Version 1 (February 4, 2020 - 23:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Manami Toriyama1,2,3,*,
- Defri Rizaldy1,2,4,
- Motoki Nakamura5,
- Fumitaka Fujita1,2,6,
- Fumihiro Okada1,6,
- Akimichi Morita5 and
- Ken J. Ishii2,7,8,*
- 1Graduate School of Pharmacological Sciences, Osaka University, Osaka, Japan
- 2Center for Vaccine and Adjuvant Research (CVAR), National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- 3Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara, Japan
- 4School of Pharmacy, Institut Teknologi Bandung, Indonesia
- 5Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
- 6Mandom Corporation, Osaka, Japan
- 7Laboratory of Vaccine Science, WPI Immunology Frontier Research Center (IFReC), Osaka University, Osaka, Japan
- 8Division of Vaccine Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- ↵*Corresponding authors kenishii{at}ims.u-tokyo.ac.jp, toriyama-m{at}bs.naist.jp